CA2710618C - Synthesis of iodixanol in methanol - Google Patents
Synthesis of iodixanol in methanol Download PDFInfo
- Publication number
- CA2710618C CA2710618C CA2710618A CA2710618A CA2710618C CA 2710618 C CA2710618 C CA 2710618C CA 2710618 A CA2710618 A CA 2710618A CA 2710618 A CA2710618 A CA 2710618A CA 2710618 C CA2710618 C CA 2710618C
- Authority
- CA
- Canada
- Prior art keywords
- iodixanol
- compound
- dimerisation
- methanol
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
This invention relates to the synthesis of iodixanol (1,3-bis(acetamido)-N,N'- bis[3,5-bis(2,3- dihydroxypropylaminocarbonyl)-2,4,6-triiodophenyl]-2-hydroxypropane), more specifically to the dimerisation of 5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo- isophthalamide with methanol as solvent.
Description
Synthesis of iodixanol in Methanol CROSS REFERENCE TO RELATED APPLICATIONS
The present application claims benefit of priority under 35 U.S.C. 119(e) to United States Provisional Application number 61/227,095 filed July 21, 2009.
TECHNICAL FIELD
This invention relates to the synthesis of iodixanol (1,3-bis(acetamido)-N,N'-bis[3,5-bis(2,3-dihydroxypropylaminocarbony1)-2,4,6-triiodopheny1]-2-hydroxypropane), more specifically to the dinnerisation of 5-acetamido-N,N'-bis(2,3-dihydroxypropy1)-2,4,6-triiodo-isophthalamide with methanol as solvent.
BACKGROUND OF THE INVENTION
lodixanol is the non-proprietory name of the chemical drug substance of a non-ionic X-ray contrast agent marketed under the trade name Visipaque TM Visipaque TM is one of the most used agents in diagnostic X-ray procedures and is manufactured in large quantities.
The manufacture of such non-ionic X-ray contrast agents involves the production of the chemical drug substance (referred to as primary production) followed by formulation into the drug product (referred to as secondary production). Primary production of iodixanol involves a multi step chemical synthesis and a thorough purification process. For a commercial drug product it is important for the primary production to be efficient and economical and to provide a drug substance fulfilling the specifications, e.g. as expressed in the US
Pharmacopea.
A number of methods are known for the preparation of iodixanol. These are all multi step chemical synthetic processes and the cost of the final formulated product thus mainly depends on these processes. It is therefore important to optimize the processes both for economic and environmental reasons.
In a preferred method for the preparation of iodixanol described in EP 108638, the final intermediate 5-acetamido-N,N'-bis(2,3-dihydroxypropyI)-2,4,6-triiodo-isophthalamide (hereinafter "Compound A") is reacted with a dimerisation agent such as epichlorohydrin to yield the drug substance, see Scheme I.
CH30 0 - ami no- 2 OH, 3-CH3OH pr opanedi ol OH
HO
CH,0 NO, HO
a 110 N 0 Acetic OH OH Anhydr i de Fl HO t\11 HO N 40 N11, NH, Compound B
OH
HO 1 0 FN,> 0 0 111 OH
Epi chl or o- H
I is hydr i n H Oil 011 HO N H H
NH HO N N
OH
0 0 1 o 011o 1 0 Compound A
iodixanol Scheme I
The reaction is usually carried out in the non-aqueous solvent 2-methoxyethanol and generally results in the conversion of 40 to 60% of Compound A to iodixanol.
The product contains large amounts of impurities and is normally purified by crystallization. Too large amounts of impurities make the purification difficult and to achieve the desired purity, the crude iodixanol produced by the synthetic chemical process is crystallized twice. The process is time consuming and takes about 3 days for the first crystallization and about 2 days for the second one. Hence, the crystallization process is very demanding in terms of time and equipment size, it will take several days to perform and is often a bottleneck in industrial scale processes.
It is hence a desire to identify alternative low-cost and easily accessible solvents that can be used in the dimerisation step and that fulfill the above-mentioned criteria.
The present application claims benefit of priority under 35 U.S.C. 119(e) to United States Provisional Application number 61/227,095 filed July 21, 2009.
TECHNICAL FIELD
This invention relates to the synthesis of iodixanol (1,3-bis(acetamido)-N,N'-bis[3,5-bis(2,3-dihydroxypropylaminocarbony1)-2,4,6-triiodopheny1]-2-hydroxypropane), more specifically to the dinnerisation of 5-acetamido-N,N'-bis(2,3-dihydroxypropy1)-2,4,6-triiodo-isophthalamide with methanol as solvent.
BACKGROUND OF THE INVENTION
lodixanol is the non-proprietory name of the chemical drug substance of a non-ionic X-ray contrast agent marketed under the trade name Visipaque TM Visipaque TM is one of the most used agents in diagnostic X-ray procedures and is manufactured in large quantities.
The manufacture of such non-ionic X-ray contrast agents involves the production of the chemical drug substance (referred to as primary production) followed by formulation into the drug product (referred to as secondary production). Primary production of iodixanol involves a multi step chemical synthesis and a thorough purification process. For a commercial drug product it is important for the primary production to be efficient and economical and to provide a drug substance fulfilling the specifications, e.g. as expressed in the US
Pharmacopea.
A number of methods are known for the preparation of iodixanol. These are all multi step chemical synthetic processes and the cost of the final formulated product thus mainly depends on these processes. It is therefore important to optimize the processes both for economic and environmental reasons.
In a preferred method for the preparation of iodixanol described in EP 108638, the final intermediate 5-acetamido-N,N'-bis(2,3-dihydroxypropyI)-2,4,6-triiodo-isophthalamide (hereinafter "Compound A") is reacted with a dimerisation agent such as epichlorohydrin to yield the drug substance, see Scheme I.
CH30 0 - ami no- 2 OH, 3-CH3OH pr opanedi ol OH
HO
CH,0 NO, HO
a 110 N 0 Acetic OH OH Anhydr i de Fl HO t\11 HO N 40 N11, NH, Compound B
OH
HO 1 0 FN,> 0 0 111 OH
Epi chl or o- H
I is hydr i n H Oil 011 HO N H H
NH HO N N
OH
0 0 1 o 011o 1 0 Compound A
iodixanol Scheme I
The reaction is usually carried out in the non-aqueous solvent 2-methoxyethanol and generally results in the conversion of 40 to 60% of Compound A to iodixanol.
The product contains large amounts of impurities and is normally purified by crystallization. Too large amounts of impurities make the purification difficult and to achieve the desired purity, the crude iodixanol produced by the synthetic chemical process is crystallized twice. The process is time consuming and takes about 3 days for the first crystallization and about 2 days for the second one. Hence, the crystallization process is very demanding in terms of time and equipment size, it will take several days to perform and is often a bottleneck in industrial scale processes.
It is hence a desire to identify alternative low-cost and easily accessible solvents that can be used in the dimerisation step and that fulfill the above-mentioned criteria.
2 WO 99/18054 describes a method of crystallization of iodixanol where a solvent mixture comprising methanol and propan-2-ol is used in the example. A vast number of other general solvents are suggested, however many of these will not be feasible in an industrial scale and there are no suggestions regarding how to perform the crystallization in terms ratios or process parameters.
US 5349085 describes a method of preparing iodixanol wherein water is used as solvent at room temperature with epichlorohydrin as dimerisation agent.
WO 98/23296 teaches the synthesis of iodixanol and mentions possible solvents in the same general way as in WO 99/18054, including alcohols.
It has now surprisingly been found that methanol can be used as solvent in the dimerization step of Compound A in an industrial scale and will fulfill the requirements listed above.
SUMMARY OF THE INVENTION
The present invention provides a large scale dimerisation process of 5-acetamido-N,N'-bis(2,3-dihydroxypropyI)-2,4,6-triiodo-isophthalamide to iodixanol.
Thus, the invention provides a process for the dimerisation of 5-acetamido-N,N1-bis(2,3-dihydroxypropyI)-2,4,6-triiodo-isophthalamide in a temperature range of about 10 to about 20 C, using methanol as solvent in a concentration of about 0.8 to about 2.0 ml solvent per g 5-acetamido-N,N'-bis(2,3-dihydroxypropy1)-2,4,6-triiodo-isophthalamide in the presence of about 0.30 to about 0.36 mole equivalents of epichlorohydrin, and wherein the reaction solution has a pH value of about 11.5 to about 12.2.
The invention also discloses a process for the dimerisation of 5-acetamido-N,N'-bis (2,3-dihydroxypropy1)-2,4,6-triiodoisophthalamide (Compound A) in a temperature
US 5349085 describes a method of preparing iodixanol wherein water is used as solvent at room temperature with epichlorohydrin as dimerisation agent.
WO 98/23296 teaches the synthesis of iodixanol and mentions possible solvents in the same general way as in WO 99/18054, including alcohols.
It has now surprisingly been found that methanol can be used as solvent in the dimerization step of Compound A in an industrial scale and will fulfill the requirements listed above.
SUMMARY OF THE INVENTION
The present invention provides a large scale dimerisation process of 5-acetamido-N,N'-bis(2,3-dihydroxypropyI)-2,4,6-triiodo-isophthalamide to iodixanol.
Thus, the invention provides a process for the dimerisation of 5-acetamido-N,N1-bis(2,3-dihydroxypropyI)-2,4,6-triiodo-isophthalamide in a temperature range of about 10 to about 20 C, using methanol as solvent in a concentration of about 0.8 to about 2.0 ml solvent per g 5-acetamido-N,N'-bis(2,3-dihydroxypropy1)-2,4,6-triiodo-isophthalamide in the presence of about 0.30 to about 0.36 mole equivalents of epichlorohydrin, and wherein the reaction solution has a pH value of about 11.5 to about 12.2.
The invention also discloses a process for the dimerisation of 5-acetamido-N,N'-bis (2,3-dihydroxypropy1)-2,4,6-triiodoisophthalamide (Compound A) in a temperature
3 range of about 10 to about 20 C. using methanol as solvent in a concentration of about 0.8 to 2.0 ml solvent per g Compound A in the presence of about 0.30 to 0.36 mole equivalents of epichlorohydrin relative to Compound A, and wherein the reaction solution has a pH value of about 11.5 to about 12.2, whereby the pH
is varied throughout the dimerisation having a higher value at the start of the dimerisation than at the end thereof, and wherein the amount of backpeaks does not exceed 2% at 55-60% conversion of Compound A to iodixanol.
The instant process uses a low cost solvent that is environmentally friendly and provides high enough yields and purity in the final product to make the manufacturing process of iodixanol economically feasible in an industrial scale.
3a DETAILED DESCRIPTION OF THE INVENTION
Crude iodixanol is obtained from the processes known from the state of art, e.g. from the dimerisation process illustrated in Scheme I above. The dimerisation step itself may be carried out as described in EP 108638 and WO 98/23296, for example using epichlorohydrin as the dimerisation agent. The reaction is usually carried out in the non-aqueous solvent 2-methoxyethanol and generally results in the conversion of 40 to 60% of Compound A to iodixanol.
Up until now methanol has been suggested as a possible alternative solvent in the dimerisation step for preparing iodixanol, however no documentation has revealed that the use of methanol can be feasible in an industrial scale. Hence, other solvents, especially 2-methoxyethanol have been used in large scale production of iodixanol.
As explained above the dimerisation generally results in the conversion of 40 to 60% of Compound A. However, the product contains large amounts of impurities and needs to undergo costly work-up procedures, like, for example, multiple crystallizations.
The most important impurities in the reaction with regard to work-up consequences are the so-called backpeaks. This term refers to retention times in reversed phase HPLC, where the backpeaks have slightly longer retention times than iodixanol itself. Most of the backpeaks are either trimers or 0-alkylated dimers. Two examples are given below:
HO
HO o 0 NH0JJ
OH OH
N11.011 ( ) 1 OH j.õõ. 1 0 Primary 0-alkyl iodixanol
is varied throughout the dimerisation having a higher value at the start of the dimerisation than at the end thereof, and wherein the amount of backpeaks does not exceed 2% at 55-60% conversion of Compound A to iodixanol.
The instant process uses a low cost solvent that is environmentally friendly and provides high enough yields and purity in the final product to make the manufacturing process of iodixanol economically feasible in an industrial scale.
3a DETAILED DESCRIPTION OF THE INVENTION
Crude iodixanol is obtained from the processes known from the state of art, e.g. from the dimerisation process illustrated in Scheme I above. The dimerisation step itself may be carried out as described in EP 108638 and WO 98/23296, for example using epichlorohydrin as the dimerisation agent. The reaction is usually carried out in the non-aqueous solvent 2-methoxyethanol and generally results in the conversion of 40 to 60% of Compound A to iodixanol.
Up until now methanol has been suggested as a possible alternative solvent in the dimerisation step for preparing iodixanol, however no documentation has revealed that the use of methanol can be feasible in an industrial scale. Hence, other solvents, especially 2-methoxyethanol have been used in large scale production of iodixanol.
As explained above the dimerisation generally results in the conversion of 40 to 60% of Compound A. However, the product contains large amounts of impurities and needs to undergo costly work-up procedures, like, for example, multiple crystallizations.
The most important impurities in the reaction with regard to work-up consequences are the so-called backpeaks. This term refers to retention times in reversed phase HPLC, where the backpeaks have slightly longer retention times than iodixanol itself. Most of the backpeaks are either trimers or 0-alkylated dimers. Two examples are given below:
HO
HO o 0 NH0JJ
OH OH
N11.011 ( ) 1 OH j.õõ. 1 0 Primary 0-alkyl iodixanol
4 =
OH OH
INCHOH
N
I le ;01-I 011 OH
OH
0"
0 CH, H3C 1 o lodfranol primary 0-alkyl trimer Other byproducts of importance are e.g. iopentol, iohexol and N-acetyl cyclised iodixanol, whose structures are shown below. lohexol and iopentol are fairly easy to remove in the subsequent crystallization of iodixanol, even when present in several weight percent.
OH
OH
OH
-N NIUJOH
HO..-NH 1 0 N- acetyl cyclized iodixanol
OH OH
INCHOH
N
I le ;01-I 011 OH
OH
0"
0 CH, H3C 1 o lodfranol primary 0-alkyl trimer Other byproducts of importance are e.g. iopentol, iohexol and N-acetyl cyclised iodixanol, whose structures are shown below. lohexol and iopentol are fairly easy to remove in the subsequent crystallization of iodixanol, even when present in several weight percent.
OH
OH
OH
-N NIUJOH
HO..-NH 1 0 N- acetyl cyclized iodixanol
5 OH
)1C:
= OH
lohexol OH
N NH OH
OH
lopentol A typical selectivity required to be able to run an economically feasible work-up and obtain the required product quality is that the amount of backpeaks should not exceed 2% at 55-60% conversion of Compound A to iodixanol. It is even more advantageous if the backpeaks do not exceed 1.4% at this conversion.
It has now surprisingly been found that under specific conditions the dimerisation step can be carried out with methanol as solvent resulting in a product that meets the requirements in order to make the overall process of manufacturing iodixanol feasible.
Thus the invention provides a process for the dimerisation of 5-acetamido-N,N11-bis(2,3-dihydroxypropy1)-2,4,6-triiodo-isophthalamide in a temperature range of about 10 to about C using methanol as solvent in a concentration of about 0.8 to about 2.0 ml solvent per g
)1C:
= OH
lohexol OH
N NH OH
OH
lopentol A typical selectivity required to be able to run an economically feasible work-up and obtain the required product quality is that the amount of backpeaks should not exceed 2% at 55-60% conversion of Compound A to iodixanol. It is even more advantageous if the backpeaks do not exceed 1.4% at this conversion.
It has now surprisingly been found that under specific conditions the dimerisation step can be carried out with methanol as solvent resulting in a product that meets the requirements in order to make the overall process of manufacturing iodixanol feasible.
Thus the invention provides a process for the dimerisation of 5-acetamido-N,N11-bis(2,3-dihydroxypropy1)-2,4,6-triiodo-isophthalamide in a temperature range of about 10 to about C using methanol as solvent in a concentration of about 0.8 to about 2.0 ml solvent per g
6 5-acetamido-N,N'-bis(2,3-dihydroxypropy1)-2,4,6-triiodo-isophthalamide in the presence of about 0.30 to about 0.36 mole equivalents of epichlorohydrin, and wherein the reaction solution has a pH value of about 11.5 to about 12.2.
The process according to the present invention is carried out with a concentration of about 0.8 to about 2.0 ml solvent per g Compound A, more preferably about 0.8 to about 1.0 and most preferably about 0.80 to about 0.85 The temperature during the dimerisation should be in the range of about 10 to about 20 C, with about 10 C being most preferred. The temperature can be constant throughout the dimerisation or varied within the specified range, preferably the temperature is lowered throughout the dimerisation.
The dimerisation agent used in the present invention is epichlorohydrin which is added in about 0.3 to about 0.36 mole equivalents.
The pH value in the reaction solution is about 11.5 to about 12.2. The pH
value can preferably be varied throughout the dimerisation having a higher value at the start of the dimerisation than at the end.
The base used to raise the pH value of the reaction solution can be any base suitable.
Preferably the base is sodium hydroxide (NaOH) or potassium hydroxide (KOH), with sodium hydroxide being most preferred.
For further adjustment of the pH value of the reaction solution any suitable acid can be used, preferably concentrated hydrochloric acid (HC1).
The dimerisation step will be allowed to proceed for several hours with a preferred reaction time of 12 to 48 hours and particularly preferred from 24 to 48 hours. The reaction may be terminated by quenching with any acid, preferably hydrochloric acid. The reaction may be monitored, e.g. by HPLC, to determine the appropriate stage at which quenching should take place.
The invention is illustrated further by the following examples that are not to be construed as limiting the invention in scope to the specific procedures or products described in them.
The process according to the present invention is carried out with a concentration of about 0.8 to about 2.0 ml solvent per g Compound A, more preferably about 0.8 to about 1.0 and most preferably about 0.80 to about 0.85 The temperature during the dimerisation should be in the range of about 10 to about 20 C, with about 10 C being most preferred. The temperature can be constant throughout the dimerisation or varied within the specified range, preferably the temperature is lowered throughout the dimerisation.
The dimerisation agent used in the present invention is epichlorohydrin which is added in about 0.3 to about 0.36 mole equivalents.
The pH value in the reaction solution is about 11.5 to about 12.2. The pH
value can preferably be varied throughout the dimerisation having a higher value at the start of the dimerisation than at the end.
The base used to raise the pH value of the reaction solution can be any base suitable.
Preferably the base is sodium hydroxide (NaOH) or potassium hydroxide (KOH), with sodium hydroxide being most preferred.
For further adjustment of the pH value of the reaction solution any suitable acid can be used, preferably concentrated hydrochloric acid (HC1).
The dimerisation step will be allowed to proceed for several hours with a preferred reaction time of 12 to 48 hours and particularly preferred from 24 to 48 hours. The reaction may be terminated by quenching with any acid, preferably hydrochloric acid. The reaction may be monitored, e.g. by HPLC, to determine the appropriate stage at which quenching should take place.
The invention is illustrated further by the following examples that are not to be construed as limiting the invention in scope to the specific procedures or products described in them.
7 EXAMPLES
Example 1 5-acetylamino-N,N'-bis (2,3-dihydroxypropyI)-2,4,6-triiodoisophthalamide (Compound A) (201.5 g, 0.268 mole) was dissolved in a solution of methanol (168 mL, 0.84 mLig Compound A) and sodium hydroxide (13.92 g, 0.348 mole, 1.30 eq) at 45 C. The mixture was cooled to 10 C and conc. hydrochloric acid (16 mL, 0.192 mole, 0.72 eq) was added followed by epichlorohydrin (7.43 g, 0.080 mole, 0.30 eq) added in one portion. After 48 hours an HPLC analysis showed the following composition: 46.8 % iodixanol, 46.3 %
Compound A, 1.09 % backpeaks, 0.06 % N-acetyl cyclized iodixanol, 3.80 %
iohexol and 1.23% iopentol.
Example 2 5-acetylamino-N,N'-bis (2,3-dihydroxypropyI)-2,4,6-triiodoisophthalamide (Compound A) (201.5 g, 0.268 mole) was dissolved in a solution of methanol (168 mL, 0.84 mUg Compound A) and sodium hydroxide (13.92 g, 0.348 mole, 1.30 eq) at 45 C. The mixture was cooled to 10 C and conc. hydrochloric acid (17 mL, 0.204 mole, 0.76 eq) was added followed by epichlorohydrin (8.92 g, 0.096 mole, 0.36 eq) added in one portion. After 48 hours an HPLC analysis showed the following composition: 50.4 % iodixanol, 40.3 %
Compound A, 1.37% backpeaks, 0.06% N-acetyl cyclized iodixanol, 5.75% iohexol and 1.37 % iopentol.
Example 3 5-acetylamino-N,N'-bis (2,3-dihydroxypropyI)-2,4,6-triiodoisophthalamide (Compound A) (201.5 g, 0.268 mole) was dissolved in a solution of methanol (200 mL, 1.00 mUg Compound A) and sodium hydroxide (13.92 g, 0.348 mole, 1.30 eq) at 45 C. The mixture was cooled to 20 C and conc. hydrochloric acid (17 mL, 0.204 mole, 0.76 eq) was added followed by epichlorohydrin (8.92 g, 0.096 mole, 0.36 eq) added in one portion. After 48 hours an HPLC analysis showed the following composition: 52.1 % iodixanol, 36.2 %
Compound A, 1.42 % backpeaks, 0.20 % N-acetyl cyclized iodixanol, 7.42 %
iohexol and 2.06 % iopentol.
Example 1 5-acetylamino-N,N'-bis (2,3-dihydroxypropyI)-2,4,6-triiodoisophthalamide (Compound A) (201.5 g, 0.268 mole) was dissolved in a solution of methanol (168 mL, 0.84 mLig Compound A) and sodium hydroxide (13.92 g, 0.348 mole, 1.30 eq) at 45 C. The mixture was cooled to 10 C and conc. hydrochloric acid (16 mL, 0.192 mole, 0.72 eq) was added followed by epichlorohydrin (7.43 g, 0.080 mole, 0.30 eq) added in one portion. After 48 hours an HPLC analysis showed the following composition: 46.8 % iodixanol, 46.3 %
Compound A, 1.09 % backpeaks, 0.06 % N-acetyl cyclized iodixanol, 3.80 %
iohexol and 1.23% iopentol.
Example 2 5-acetylamino-N,N'-bis (2,3-dihydroxypropyI)-2,4,6-triiodoisophthalamide (Compound A) (201.5 g, 0.268 mole) was dissolved in a solution of methanol (168 mL, 0.84 mUg Compound A) and sodium hydroxide (13.92 g, 0.348 mole, 1.30 eq) at 45 C. The mixture was cooled to 10 C and conc. hydrochloric acid (17 mL, 0.204 mole, 0.76 eq) was added followed by epichlorohydrin (8.92 g, 0.096 mole, 0.36 eq) added in one portion. After 48 hours an HPLC analysis showed the following composition: 50.4 % iodixanol, 40.3 %
Compound A, 1.37% backpeaks, 0.06% N-acetyl cyclized iodixanol, 5.75% iohexol and 1.37 % iopentol.
Example 3 5-acetylamino-N,N'-bis (2,3-dihydroxypropyI)-2,4,6-triiodoisophthalamide (Compound A) (201.5 g, 0.268 mole) was dissolved in a solution of methanol (200 mL, 1.00 mUg Compound A) and sodium hydroxide (13.92 g, 0.348 mole, 1.30 eq) at 45 C. The mixture was cooled to 20 C and conc. hydrochloric acid (17 mL, 0.204 mole, 0.76 eq) was added followed by epichlorohydrin (8.92 g, 0.096 mole, 0.36 eq) added in one portion. After 48 hours an HPLC analysis showed the following composition: 52.1 % iodixanol, 36.2 %
Compound A, 1.42 % backpeaks, 0.20 % N-acetyl cyclized iodixanol, 7.42 %
iohexol and 2.06 % iopentol.
8 =
Example 4 5-acetylamino-N,N'-bis (2,3-dihydroxypropyI)-2,4,6-triiodoisophthalamide (Compound A) (201.5 g, 0.268 mole) was dissolved in a solution of methanol (168 mL, 0.84 mL/g .
Compound A) and sodium hydroxide (13.92 g, 0.348 mole, 1.30 eq) at 45 C. The mixture was cooled to 15 C and conc. hydrochloric acid (17 mL, 0.204 mole, 0.76 eq) was added followed by epichlorohydrin (8.17 g, 0.088 mole, 0.33 eq) added in one portion. After 48 hours an HPLC analysis showed the following composition: 50.9 % iodixanol, 39.1 %
Compound A, 1.40 % backpeaks, 0.13 % N-acetyl cyclized iodixanol, 7.00 %
iohexol and 1.59% iopentol.
=
Example 4 5-acetylamino-N,N'-bis (2,3-dihydroxypropyI)-2,4,6-triiodoisophthalamide (Compound A) (201.5 g, 0.268 mole) was dissolved in a solution of methanol (168 mL, 0.84 mL/g .
Compound A) and sodium hydroxide (13.92 g, 0.348 mole, 1.30 eq) at 45 C. The mixture was cooled to 15 C and conc. hydrochloric acid (17 mL, 0.204 mole, 0.76 eq) was added followed by epichlorohydrin (8.17 g, 0.088 mole, 0.33 eq) added in one portion. After 48 hours an HPLC analysis showed the following composition: 50.9 % iodixanol, 39.1 %
Compound A, 1.40 % backpeaks, 0.13 % N-acetyl cyclized iodixanol, 7.00 %
iohexol and 1.59% iopentol.
=
9 =
Claims (4)
1. A process for the dimerisation of 5-acetamido-N,N'-bis (2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (Compound A) in a temperature range of about 10 to about 20°C. using methanol as solvent in a concentration of about 0.8 to 2.0 ml solvent per g Compound A in the presence of about 0.30 to 0.36 mole equivalents of epichlorohydrin relative to Compound A, and wherein the reaction solution has a pH value of about 11.5 to about 12.2, whereby the pH is varied throughout the dimerisation having a higher value at the start of the dimerisation than at the end thereof, and wherein the amount of backpeaks does not exceed 2% at 60% conversion of Compound A to iodixanol.
2. The process of claim 1, wherein said amount of backpeaks does not exceed 1.4% at 55-60% conversion of Compound A to iodixanol.
3. The process of claim 2, wherein said temperature range is a temperature of about 10°C.
4. The process of claim 1, wherein said temperature range is about 10°C.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22709509P | 2009-07-21 | 2009-07-21 | |
| US61/227,095 | 2009-07-21 | ||
| US12/621,551 US8962886B2 (en) | 2009-07-21 | 2009-11-19 | Synthesis of iodixanol in methanol |
| US12/621,551 | 2009-11-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2710618A1 CA2710618A1 (en) | 2011-01-21 |
| CA2710618C true CA2710618C (en) | 2017-07-18 |
Family
ID=43495955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2710618A Active CA2710618C (en) | 2009-07-21 | 2010-07-20 | Synthesis of iodixanol in methanol |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2710618C (en) |
-
2010
- 2010-07-20 CA CA2710618A patent/CA2710618C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2710618A1 (en) | 2011-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1960349B1 (en) | Purification of iodixanol | |
| CA2881707C (en) | Preparation of intermediates of x-ray contrast agents | |
| KR101083147B1 (en) | Process for iohexol manufacture | |
| AU2010224945B2 (en) | Process for the preparation of triiodinated carboxylic aromatic derivatives | |
| CA2710618C (en) | Synthesis of iodixanol in methanol | |
| EP2279998B1 (en) | Synthesis of iodixanol in propyleneglycol | |
| EP2277853B1 (en) | Synthesis of iodixanol in methanol | |
| CA2710422C (en) | Synthesis of iodixanol in 1-methoxy-2-propanol and water or methanol | |
| EP2277854B1 (en) | Synthesis of iodixanol in 1-methoxy-2-propanol and water or methanol | |
| EP2277852B1 (en) | Synthesis of iodixanol in water | |
| CA2707173C (en) | Crystallization of iodixanol in isopropanol and methanol | |
| CA2710598C (en) | Synthesis of iodixanol in water | |
| EP2289870B1 (en) | Method for purifying 5-amino-N,N'-bis(2,3-dihydroxypropyl)-isophthalamide, an intermediate in the preparation of non-ionic X-ray contrast agents | |
| CA2710111A1 (en) | Synthesis of iodixanol in propyleneglycol | |
| CA2695551C (en) | Alternative dimerisation reagents for synthesis of iodixanol | |
| CA2710577C (en) | Crystallization of iodixanol using milling | |
| CA2710642C (en) | Crystallization of iodixanol using ultrasound | |
| CA2710582A1 (en) | Decolorizing contrast media intermediates | |
| CA2710090A1 (en) | Acetylation using reduced volume of acetic acid anhydride for synthesizing non-ionic x-ray contrast agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150708 |